Moxifloxacin Ophthalmic Solution USP, 0.5% has an estimated market size of US$ 68 million for twelve months ending December 2018 according to IQVIA.
The scheme provides for -
Amalgamation of the Transferor Company 1, Transferor Company 2, Transferor Company 3 and Transferor Company 4 with the Transferee Company; and
Amalgamation of the Company with the Transferee Company.
SPARC had out-licensed ELEPSIATM XR to SPGFZE in July 2016; and was eligible for sales linked milestone and royalties upon commercialization of Elepsia TM XR.
Consequently, SPARC would find another partner for commercialising the captioned product.
Long Term / Short Term Bank Facilities - CARE BB; Negative / CARE A4 (Revised from CARE BBB-; Negative / CARE A3)
Long Term Bank Facilities - CARE BB; Negative (Revised from CARE BBB-; Negative)
Commercial Paper - CARE A4 (Revised from CARE A3)